Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway

Liang N. Zhang, Phil Karp, Christopher J. Gerard, Eric Pastor, Douglas Laux, Keith Munson, Ziying Yan, Xiaoming Liu, Simon Godwin, Christie P. Thomas, Joseph Zabner, Huidong Shi, Charles W. Caldwell, Richard Peluso, Barrie Carter, John F. Engelhardt

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Pharmacologic- and gene-based therapies have historically been developed as two independent therapeutic platforms for cystic fibrosis (CF) lung disease. Inhibition of the dysregulated epithelial Na channel (ENaC) is one pharmacologic approach to enhance airway clearance in CF. We investigated pharmacologic approaches to enhance CFTR gene delivery with recombinant adeno-associated virus (rAAV) and identified compounds that significantly improved viral transduction while simultaneously inhibiting ENaC activity through an unrelated mechanism. Treatment of human CF airway epithelia with proteasome modulating agents (LLnL and doxorubicin) at the time of rAAV2 or rAAV2/5 infection dramatically enhanced CFTR gene delivery and correction of CFTR-mediated short-circuit currents. Surprisingly, these agents also facilitated long-term (15-day) functional inhibition of ENaC currents independent of CFTR vector administration. Inhibition of ENaC activity was predominantly attributed to a doxorubicin-dependent decrease in γ-ENaC subunit mRNA expression and an increase in γ-ENaC promoter methylation. This is the first report to describe the identification of compounds with dual therapeutic action that are able to enhance the efficacy of CFTR gene therapy to the airway while simultaneously ameliorating primary aspects of CF disease pathophysiology. The identification of such compounds mark a new area for drug development, not only for CF, but also for other gene therapy disease targets.

Original languageEnglish (US)
Pages (from-to)990-1002
Number of pages13
JournalMolecular Therapy
Volume10
Issue number6
DOIs
StatePublished - Dec 1 2004

Fingerprint

Epithelial Sodium Channels
Proteasome Endopeptidase Complex
Cystic Fibrosis
Genetic Therapy
Doxorubicin
Therapeutics
Dependovirus
Methylation
Lung Diseases
Genes
Epithelium
Messenger RNA
Infection
Pharmaceutical Preparations

Keywords

  • AAV
  • Adeno-associated virus
  • CFTR
  • Cystic fibrosis
  • ENaC
  • Gene therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Zhang, L. N., Karp, P., Gerard, C. J., Pastor, E., Laux, D., Munson, K., ... Engelhardt, J. F. (2004). Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway. Molecular Therapy, 10(6), 990-1002. https://doi.org/10.1016/j.ymthe.2004.08.009

Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway. / Zhang, Liang N.; Karp, Phil; Gerard, Christopher J.; Pastor, Eric; Laux, Douglas; Munson, Keith; Yan, Ziying; Liu, Xiaoming; Godwin, Simon; Thomas, Christie P.; Zabner, Joseph; Shi, Huidong; Caldwell, Charles W.; Peluso, Richard; Carter, Barrie; Engelhardt, John F.

In: Molecular Therapy, Vol. 10, No. 6, 01.12.2004, p. 990-1002.

Research output: Contribution to journalArticle

Zhang, LN, Karp, P, Gerard, CJ, Pastor, E, Laux, D, Munson, K, Yan, Z, Liu, X, Godwin, S, Thomas, CP, Zabner, J, Shi, H, Caldwell, CW, Peluso, R, Carter, B & Engelhardt, JF 2004, 'Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway', Molecular Therapy, vol. 10, no. 6, pp. 990-1002. https://doi.org/10.1016/j.ymthe.2004.08.009
Zhang, Liang N. ; Karp, Phil ; Gerard, Christopher J. ; Pastor, Eric ; Laux, Douglas ; Munson, Keith ; Yan, Ziying ; Liu, Xiaoming ; Godwin, Simon ; Thomas, Christie P. ; Zabner, Joseph ; Shi, Huidong ; Caldwell, Charles W. ; Peluso, Richard ; Carter, Barrie ; Engelhardt, John F. / Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway. In: Molecular Therapy. 2004 ; Vol. 10, No. 6. pp. 990-1002.
@article{a3835eb4ec06440dae947ba7e1bf480a,
title = "Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway",
abstract = "Pharmacologic- and gene-based therapies have historically been developed as two independent therapeutic platforms for cystic fibrosis (CF) lung disease. Inhibition of the dysregulated epithelial Na channel (ENaC) is one pharmacologic approach to enhance airway clearance in CF. We investigated pharmacologic approaches to enhance CFTR gene delivery with recombinant adeno-associated virus (rAAV) and identified compounds that significantly improved viral transduction while simultaneously inhibiting ENaC activity through an unrelated mechanism. Treatment of human CF airway epithelia with proteasome modulating agents (LLnL and doxorubicin) at the time of rAAV2 or rAAV2/5 infection dramatically enhanced CFTR gene delivery and correction of CFTR-mediated short-circuit currents. Surprisingly, these agents also facilitated long-term (15-day) functional inhibition of ENaC currents independent of CFTR vector administration. Inhibition of ENaC activity was predominantly attributed to a doxorubicin-dependent decrease in γ-ENaC subunit mRNA expression and an increase in γ-ENaC promoter methylation. This is the first report to describe the identification of compounds with dual therapeutic action that are able to enhance the efficacy of CFTR gene therapy to the airway while simultaneously ameliorating primary aspects of CF disease pathophysiology. The identification of such compounds mark a new area for drug development, not only for CF, but also for other gene therapy disease targets.",
keywords = "AAV, Adeno-associated virus, CFTR, Cystic fibrosis, ENaC, Gene therapy",
author = "Zhang, {Liang N.} and Phil Karp and Gerard, {Christopher J.} and Eric Pastor and Douglas Laux and Keith Munson and Ziying Yan and Xiaoming Liu and Simon Godwin and Thomas, {Christie P.} and Joseph Zabner and Huidong Shi and Caldwell, {Charles W.} and Richard Peluso and Barrie Carter and Engelhardt, {John F.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1016/j.ymthe.2004.08.009",
language = "English (US)",
volume = "10",
pages = "990--1002",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway

AU - Zhang, Liang N.

AU - Karp, Phil

AU - Gerard, Christopher J.

AU - Pastor, Eric

AU - Laux, Douglas

AU - Munson, Keith

AU - Yan, Ziying

AU - Liu, Xiaoming

AU - Godwin, Simon

AU - Thomas, Christie P.

AU - Zabner, Joseph

AU - Shi, Huidong

AU - Caldwell, Charles W.

AU - Peluso, Richard

AU - Carter, Barrie

AU - Engelhardt, John F.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Pharmacologic- and gene-based therapies have historically been developed as two independent therapeutic platforms for cystic fibrosis (CF) lung disease. Inhibition of the dysregulated epithelial Na channel (ENaC) is one pharmacologic approach to enhance airway clearance in CF. We investigated pharmacologic approaches to enhance CFTR gene delivery with recombinant adeno-associated virus (rAAV) and identified compounds that significantly improved viral transduction while simultaneously inhibiting ENaC activity through an unrelated mechanism. Treatment of human CF airway epithelia with proteasome modulating agents (LLnL and doxorubicin) at the time of rAAV2 or rAAV2/5 infection dramatically enhanced CFTR gene delivery and correction of CFTR-mediated short-circuit currents. Surprisingly, these agents also facilitated long-term (15-day) functional inhibition of ENaC currents independent of CFTR vector administration. Inhibition of ENaC activity was predominantly attributed to a doxorubicin-dependent decrease in γ-ENaC subunit mRNA expression and an increase in γ-ENaC promoter methylation. This is the first report to describe the identification of compounds with dual therapeutic action that are able to enhance the efficacy of CFTR gene therapy to the airway while simultaneously ameliorating primary aspects of CF disease pathophysiology. The identification of such compounds mark a new area for drug development, not only for CF, but also for other gene therapy disease targets.

AB - Pharmacologic- and gene-based therapies have historically been developed as two independent therapeutic platforms for cystic fibrosis (CF) lung disease. Inhibition of the dysregulated epithelial Na channel (ENaC) is one pharmacologic approach to enhance airway clearance in CF. We investigated pharmacologic approaches to enhance CFTR gene delivery with recombinant adeno-associated virus (rAAV) and identified compounds that significantly improved viral transduction while simultaneously inhibiting ENaC activity through an unrelated mechanism. Treatment of human CF airway epithelia with proteasome modulating agents (LLnL and doxorubicin) at the time of rAAV2 or rAAV2/5 infection dramatically enhanced CFTR gene delivery and correction of CFTR-mediated short-circuit currents. Surprisingly, these agents also facilitated long-term (15-day) functional inhibition of ENaC currents independent of CFTR vector administration. Inhibition of ENaC activity was predominantly attributed to a doxorubicin-dependent decrease in γ-ENaC subunit mRNA expression and an increase in γ-ENaC promoter methylation. This is the first report to describe the identification of compounds with dual therapeutic action that are able to enhance the efficacy of CFTR gene therapy to the airway while simultaneously ameliorating primary aspects of CF disease pathophysiology. The identification of such compounds mark a new area for drug development, not only for CF, but also for other gene therapy disease targets.

KW - AAV

KW - Adeno-associated virus

KW - CFTR

KW - Cystic fibrosis

KW - ENaC

KW - Gene therapy

UR - http://www.scopus.com/inward/record.url?scp=10344225049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10344225049&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2004.08.009

DO - 10.1016/j.ymthe.2004.08.009

M3 - Article

C2 - 15564131

AN - SCOPUS:10344225049

VL - 10

SP - 990

EP - 1002

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 6

ER -